Table 1.
Characteristics of studies included in the meta-analysis.
| Author, year of publication | No. of patients | Micro/ Macro | Mean follow up time (months) | Mean age(year)* | Male/Female $ | First-line treatment | Mean PRL before Treatment (ng/ml) ¥ | Normalization of PRL in therapy (Medical cohort) | Short term remission rate (Surgical cohort) | Long-term remission rate |
|---|---|---|---|---|---|---|---|---|---|---|
| MEDICATION COHORT | ||||||||||
| (28) | 89 | Micro:30 | >12 | 33 | 1/29 | CAB or BRC | 219.2 ± 460.6 | Y (5.0 ± 5.1) | NA | 13 (43.3%) |
| Macro:59 | 34 | 26/33 | 936.5 ± 1947 | Y (4.2 ± 4.6) | 25 (42.4%) | |||||
| (29) | 50 | Micro:41 | >12 | 35.1 | 5/45 | CAB or BRC | 93.3 | Y | NA | 32 (78.0%) |
| Macro:9 | 521 | Y | 4 (44.4%) | |||||||
| (25) | 74 | Micro:56 | >12 | 42.4 ± 9.9 | 6/50 | CAB | 113.5 ± 54.12 | Y (7.3 ± 4.3) | NA | 31 (55.3%) |
| Macro:18 | 70 ± 10.9 | 13/5 | 258.9 ± 211.3 | Y (13.4 ± 14.1) | 9 (50.0%) | |||||
| (11) | 67 | Micro:23 | >12 | 34.3 ± 11.2 | 2/21 | CAB or BRC | 142 ± 35 ~ 207 ± 112 | Y | NA | 15 (65.2%) |
| Macro:44 | 15/29 | 938 ± 1369 ~ 2902 ± 4591 | Y | 16 (36.4%) | ||||||
| (10) | 42 | Micro:31 | >12 | 44 | 5/26 | CAB | 73.0 | Y (3.6) | NA | 15 (48.4%) |
| Macro:11 | 54 | 7/4 | 310 | Y (1.9) | 5 (45.5%) | |||||
| (9) | 194 | Micro:115 | >12 | 32 | 12/103 | CAB | 222.5 | Y | NA | 76 (66.1%) |
| Macro:79 | 44 | 36/43 | 1261.8 | Y | 37 (46.9%) | |||||
| (20) | 89 | Micro: 89 | >12 | 32.7 | 5/84 | CAB or BRC | 100.9 | Y | NA | 32 (36.0%) |
| SURGERY COHORT # | ||||||||||
| (27) | 71 | Micro:41 Macro:30 | >12 | 33.3 ± 10 | 0/71 | TS | 105 | NA | 67% | 90% |
| 303 | NA | 61% | 81% | |||||||
| (26) | 15 | Micro:5 Macro:10 | >12 | 42.8 ± 13 | 5/0 | TS | 220 | NA | 80% | 4 (80.0%) |
| 10/0 | 3130 | NA | 30% | 8 (80.0%) | ||||||
| (24) | 65 | Micro:54 Macro:11 | >12 | 37.11 | 16/38 | TS | 170.07 ± 120.16 | NA | ND | 53 (98.1%) |
| 9/2 | 266.05 ± 190.77 | 7 (63.6%) | ||||||||
| (23) | 10 | Micro:10 | >12 | 31.0 ± 8.2 | 0/10 | TS | 108.9 | NA | ND | 9 (90.0%) |
| (22) | 9 | Micro:2 | >12 | 19 | 0/2 | TS | 123.50 | NA | 100% | 2 (100%) |
| Macro:7 | 50 | 5/2 | 3171.28 | NA | 42.9% | 5 (71.4%) | ||||
| (21) | 34 | Micro:24 | >12 | 30.2 | 4/20 | TS | 106.5 | NA | 91.7% | 22 (91.7%) |
| Macro:10 | 32.6 | 0/10 | 273 | NA | 100% | 8 (80.0%) | ||||
Y, yes; ND, no data; NA, not applicable; TS, Transsphenoidal surgery;
#
Part of patients needed postoperative administration of DAs for long-term normalization of PRL.
Potential sources of heterogeneity between medication and surgery cohorts were estimated.
*
P = 0.534;
$
P = 0.836; ¥: Micro: P = 0.485; Macro: P = 1.000.